MDCK-MRP2 - Dkfz

214
Forschungsschwerpunkt C
Krebsrisikofaktoren und Krebsprävention
[68] Korz C., Pscherer A., Benner A., Mertens D., Schaffner
C., Leupolt E., Döhner H., Stilgenbauer S., Lichter P.: Evidence
for distinct pathomechanisms in B-cell chronic lymphocytic leukemia
and mantle cell lymphoma by quantitative expression analysis
of cell cycle and apoptosis-associated genes. Blood 99 (12)
4554-4561, 2002.
[69] Kröber A., Seiler T., Benner A., Bullinger L., Brückle E.,
Lichter P., Döhner H., Stilgenbauer S.: V(H) mutation status,
CD38 expression level, genomic aberrations, and survival in
chronic lymphocytic leukemia. Blood 100 (4) 1410-1416, 2002.
[70] Kuntz C., Kienle P., Schmeding M., Benner A., Autschbach
F., Schwalbach P.: Comparison of laparoscopic versus conventional
technique in colonic and liver resection in a tumor-bearing
small animal model. Surg.Endosc. 16 (8) 1175-1181, 2002.
[71] Laack E., Mende T., Dürk H., Kneba M., Dickgreber N.,
Welte T., Müller T., Scholtze J., Graeven U., Jasiewicz Y., Edler
L., Hossfeld D.K.: Gemcitabine, vinorelbine and cisplatin combination
chemotherapy in advanced non-small cell lung cancer: a
phase II trial. Europ.J.Cancer 38 654-660, 2002.
[72] Laack E., Nikbakht H., Peters A., Kugler C., Jasiewicz Y.,
Edler L., Brümmer J., Schumacher U., Hossfeld D.K.: Expression
of CEACAM1 in adenocarcinoma of the lung: a factor of independent
prognostic significance. J.Clin.Oncol. 20 (21) 4279-4284,
2002.
[73] Laack E., Nikbakht H., Peters A., Kugler C., Jasiewicz Y.,
Edler L., Hossfeld D.K., Schumacher U.: Lectin histochemistry of
resected adenocarcinoma of the lung. Helix pomatia agglutinin
binding is an independent prognostic factor. Am.J.Pathol. 160 (3)
1001-1008, 2002.
[74] Laufs S., Gentner B., Nagy K.Z., Jauch A., Benner A.,
Naundorf S., Kühlcke K., Schiedlmeier B., Ho A.D., Zeller W.J.,
Frühauf S.: Retroviral vector integration occurs into preferred
genomic targets of human bone marrow repopulating cells. Blood
101 (6) 2191-2198, 2003.
[75] Leupolt E., Stilgenbauer S., Kröber A., Benner A., Lichter
P., Döhner H.: Clonal evolution in B-CLL-association with IgVH homology,
disease progression and in-vivo resistance to therapy.
Onkol. 25(S4), p.172 (608), 2002.
[76] Liebisch P., Erne S., Scheck D., Wellmann A., Einsele H.,
Straka C., Goldschmidt H., Benner A., Stilgenbauer S., Döhner
H.: In multiple myeloma, five common genomic aberrations (+1q,
+9q, +11q, 13q-, t14q) display a non-random distribution and
suggest novel pathogenetic pathways. Onkol. 26(S5), p.121
(P684), 2003.
[77] Liebisch P., Wellmann A., Wendl C., Roth K., Benner A.,
Stilgenbauer S., Döhner H.: Trisomies of chromosomes 1q, 9q,
and 11q in multiple myeloma - non-random distribution of three
highly frequent aberrations. Onkol. 25(S4), pp.73-74 (252),
2002.
[78] Lutz W.K., Vamvakas S., Kopp-Schneider A., Schlatter J.,
Stopper H.: Deviation from additivity in mixture toxicity: relevance
of nonlinear dose-response relationships and cell line differences
in genotoxicity assays with combinations of chemical
mutagens and y-radiation. Environ.Hlth.Persp. 110 (Suppl.6)
915-918, 2002.
[79] Manegold C., Mezger J., Pilz L.R., Schott K., Koschel G.,
Hruska D.: Single-agent gemcitabine and docetaxel given sequentially
every 3 weeks in advanced NSCLC: final results of a
randomized phase-II-study show effective treatment. Onkol.
26(S5), p.140 (P753), 2003.
[80] Manegold C., Pilz L., Koschel G., Schott K., Hruska D.,
Mezger J.: Final results from two randomized phase II studies
with single agent gemcitabine and docetaxel given sequentially in
various doses and schedules are effective in advanced NSCLC.
Proc.ASCO (No.1273), 2002.
[81] Manegold C., Pilz L., Koschel G., Schott K., Hruska D.,
Mezger J.: Survival data from two randomized phase II studies
show effectiveness for therapy of advanced NSCLC by single
agent gemcitabine and docetaxel given sequentially in various
doses and schedules. J.Cancer Res.Clin.Oncol. 128(Suppl.1),
p.74 (P376), 2002.
C060
Biostatistik
DKFZ 2004: Wissenschaftlicher Ergebnisbericht 2002 - 2003
[82] Markowetz F., Edler L., Vingron M.: Support vector machines
for protein fold class prediction. Biometr.J. 45 (3) 377-
389, 2003.
[83] Möhler T., Hillengass J., Höpfner S., Benner A., Schlenzka
J., Neben K., Egerer G., Görner M., Ho A.D., Goldschmidt H.:
Thalidomide and CED chemotherapy followed by stem cell transplantation
for poor prognosis multiple myeloma. Onkol. 26(S5),
p.132 (P720), 2003.
[84] Müller A., Drings P., Rittgen W., Manegold C.: CNS-relapse
after multimodality treatment of stage III non-small cell
lung cancer. J.Cancer Res.Clin.Oncol. 128(Suppl.1), p.76
(P384), 2002.
[85] Neben K., Korshunov A., Benner A., Wrobel G., Hahn M.,
Golanov A., Lichter P.: Identification of novel prognostic markers
in medulloblastoma by gene expression experiments. Onkol.
26(S5), p.37 (V352), 2003.
[86] Neben K., Korshunov A., Wrobel G., Tews B., Benner A.,
Hahn M., Golanov A., Lichter P.: Gene expression patterns in
ependymoma correlate with tumor location and patient age.
Onkol. 26(S5), p.203 (P981), 2003.
[87] Oberemm A., Querfurth N., Dieterich A., Meckert C.,
Brandenburger L., Herzig A., Lindner Y., Krause E., Ittrich C.,
Kopp-Schneider A., Richter-Reichhelm H.B., Gundert-Remy U.:
Proteomic analysis of TCDD-mediated effects in marmoset liver
and thymus. Naunyn-Schmiedeb.Arch.Pharmacol. 367(Suppl.1),
p.R153 (599), 2003.
[88] Oberemm A., Querfurth N., Meckert C., Brandenburger L.,
Herzig A., Kalenberg K., Krause E., Ittrich C., Kopp-Schneider
A., Hellmann J., Bannasch P., Richter-Reichhelm H.B., Gundert-
Remy U.: Proteomic investigation into n-nitrosomorpholine mediated
changes in rat liver. Toxicol.Lett. 144(Suppl.1), p.s103
(379), 2003.
[89] Öhm C., Ittrich C., Mezger J., Langenbuch T., Eckardt
M.J., Lehban H., Rehm M., Schulz G., Seipelt G., Ehlert T., Stauch
M., Wolters U., Edler L.: Gemcitabine and vindesin combination
regimen in inoperable metastatic non-small cell lung cancer: a
phase II study. Onkol. 26(S5), p.141 (P754), 2003.
[90] Pauli T., Pilz L., Rittgen W.: A stochastic model of the
human skin under consideration of cell proliferation and differentiation
and its realization as a simulation model.
Inf.Biom.Epidem.Med.Biol. 34(3), pp.309-311, 2003.
[91] Renwick A.G., Barlow S.M., Hertz-Piccioto I., Boobis A.R.,
Dybing E., Edler L., Eisenbrand G., Greig J.B., Kleiner J., Lambe
J., Müller D.J.G., Smith M.R., Tritscher A., Tuijtelaars S., van den
Brandt P., Walker R., Kroes R.: Risk characterization of chemicals
in food and diet. Final part of Food Safety in Europe (FOSIE):
Risk assessment of chemicals in food and diet (EC concerted action
QLK1-1999-00156). Food Chem.Toxicol. 41 (9 special issue)
1211-1271, 2003.
[92] Salowsky R., Heiss N.S., Benner A., Wittig R., Poustka A.:
Basal transcription activity of the dyskeratosis congenita gene is
mediated by Sp1 and Sp3 and a patient mutation in a Sp1 binding
site is associated with decreased promoter activity. Gene 293 (1-
2) 9-19, 2002.
[93] Schlenk R.F., Benner A., Hartmann F., del Valle F., Weber
C., Pralle H., Fischer J., Gunzer U., Pezzutto A., Weber W.,
Grimminger W., Preiss J., Hensel M., Fröhling S., Döhner K., Haas
R., Döhner H.: Risk-adapted postremission therapy in acute myeloid
leukemia: results of the German multicenter AML HD93
treatment trial. Leukem. 17 (8) 1521-1528, 2003.
[94] Schlenk R.F., Fröhling S., Benner A., Addamo B.,
Hartmann F., del Valle F., Pralle H., Fischer J.T., Kölbel C.B.,
Grimminger W., Mergenthaler H.G., Preiss J., Hensel M.,
Glasmacher A., Peschel C., Waterhouse C., Salwender H.,
Biedermann H.G., Kneba M., Kremers S., Koller E., Griesinger F.,
Döhner K., Haas R.: Phase III- study of all-trans retinoic acid in
previously untreated patients 61 years or older with acute myeloid
leukemia: AMLSG ULM study HD98B. Onkol. 26(S5), p.1
(V137), 2003.